Loading clinical trials...
Loading clinical trials...
A Phase II Randomized Open-Label Trial of Levetiracetam for Prevention of Seizures in Patients With Brain Metastases in Primary Motor Cortex
Conditions
Interventions
Levetiracetam (Keppra)
Locations
1
United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Start Date
December 23, 2025
Primary Completion Date
February 1, 2029
Completion Date
February 1, 2030
Last Updated
March 19, 2026
NCT05077904
NCT06388707
NCT05667142
NCT07234695
NCT03492060
NCT07141329
Lead Sponsor
Ayal A. Aizer, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions